Analyst Cuts Myriad Genetics Inc. To Sell; Ups Alere Inc.

Myriad Genetics Inc. (NASDAQ: MYGN) will face mounting evidence in the first-quarter earnings season of dwindling market share and increased price competition, an analyst said Monday.Goldman Sachs' Isaac Ro downgraded the Salt Lake City molecular diagnostic company to Sell, from Neutral, slashing his price target 19 percent to $25.Ro also expects Myriad's new investments in growth will prove more costly than expected.While adjusting several price targets among diagnostics companies, the analyst also downgraded Exact Sciences Corp. (NASDAQ: EXAS) to Neutral and raised his rating on Alere Inc. (NYSE: ALR), also to Neutral.A significant speed-up in testing volume for Exact Sciences is unlikely until 2016, Ro said, while adoption of its Cologuard product will be slower than expected.Ro cut his price target on Exact by 17 percent to $24.At Alere, Ro cited the company's recent, positive fourth-quarter surprise and said its plan to focus on toxicology as well as point-of-care diagnostic products may produce wider margins.Ro raised his target on Alere 12 percent to $47, but said he'd wait for more evidence of improved earnings before becoming bullish.Ro also cut his target on T2 Biosystems Inc. (NASDAQ: TTOO) 16 percent to $21 and raised his target on Cepheid (NASDAQ: CPHD) 27 percent to $59, maintaining Neutral ratings on each company.Hologic Inc. (NASDAQ: HOLX), the only Buy-rated company on Ro's list, got a 14 percent price target boost to $39. Hologic has sizable international growth opportunities, in Ro's viewTeekay Offshore Partners L.P.(NYSE: TOO)